Pharmaceutical Strategic Alliances: Sharing and Optimizing Risk
Executive Summary
If there was an overriding theme at this year's PSA, it was the search for balance of risk in pharma-biotech collaborations. PSA also showcased Big Pharma's efforts to expand in large molecules, and its attempts to dilute risk internally, by adopting the strategic habits of biotech companies.You may also be interested in...
Bristol Revs Its R&D Engine: An Interview with Elliott Sigal and Francis Cuss
Bristol Revs Its R&D Engine: An Interview with Elliott Sigal and Francis Cuss
Restructuring Roche's R&D: An Interview with Lee Babiss
Need a specific report? 1000+ reports available
Buy Reports